Solicited local reactions at the injection site (pain, tenderness, erythema/redness, induration/swelling) recorded up to 7 days after each immunization.;Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) recorded up to 7 days after each immunization.;The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE):;The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE):

Solicited local reactions at the injection site (pain, tenderness, erythema/redness, induration/swelling) recorded up to 7 days after each immunization.;Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) recorded up to 7 days after each immunization.;The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE):;The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE):

The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE):;Solicited local reactions at the injection site (pain, tenderness, erythema/redness, induration/swelling) recorded up to 7±1 days after each immunization.;Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) recorded up to 7±1 days after each immunization.;The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE):

The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE):;Solicited local reactions at the injection site (pain, tenderness, erythema/redness, induration/swelling) recorded up to 7±1 days after each immunization.;Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) recorded up to 7±1 days after each immunization.;The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE):